HPV and Systemic Response in Cervical Intraepithelial Neoplasia
DOI:
https://doi.org/10.21270/archi.v12i10.6235Keywords:
Blood Cell Count, Cervical Intraepithelial Neoplasia, Papillomaviridae, Platelet CountAbstract
Objectives: to verify whether there is an association of low and high-risk HPV with blood count parameters in patients with cervical intraepithelial neoplasia. Methods: We prospectively evaluated 48 patients with Pap smear showing low or high-grade intraepithelial lesion, submitted to collection of material to perform PCR for high-risk and low-risk HPV. The following blood count parameters were evaluated: hemoglobin, red blood cells, hematocrit, absolute number of leukocytes, neutrophils, lymphocytes, eosinophils, basophils, monocytes and platelets, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and Red Cell Distribution Width (RDW). Receiver operating characteristic (ROC) curve was used to obtain the area under the curve (AUC) relating the positivity or not of HPV with the blood count parameters evaluated. Mann-Whitney test and multivariate analysis were performed, with level of significance less than 0.05. Results: Relating the positivity or not of HPV with the blood count parameters (Roc curves), there was statistical significance only between high-risk HPV and the platelet count (sensitivity=75%, specificity=66.7%, AUC=0.674, p=0.039). Platelet count ≤ 177,000/mm3 is associated with high-risk HPV. Subsequently, the multivariate analysis was performed, and the absolute value of platelets was considered an independent variable in this association with high-risk oncogenic HPV. Conclusion: A systemic response is found with the presence of high-risk HPV in CIN. Thus, platelet count ≤ 177,000/mm3 is associated with high-risk HPV.
Downloads
References
Martins LFL, Thuler LCS, Valente JG. Cobertura do exame de Papanicolaou no Brasil e seus fatores determinantes: uma revisão sistemática da literatura. Rev Bras Ginecol Obstet 2005; 27(8):485-92.
zur Hausen H. Papillomavirus and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50.
INCA, 2020. Incidência do Câncer no Brasil. https://www.inca.gov.br/controle-do-cancer-do-colo-do-utero/conceito-e-magnitude. Accessed may 2022.
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802.
Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244-65.
Chichareon S, Herrero R, Muñoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk Factors for Cervical Cancer in Thailand: a Case-Control Study, J Natl Cancer Inst 1998;90(1):50-7.
Nayar R, Wilbur DC, editors. The Bethesda system for reporting cervical cytology: definitions, criteria and explanatory notes. Third edition. New York: Springer International Publishing Switzerland; 2015
Tavares-Murta BM, Mendonça MAO, Duarte NL, Silva JA, Mutão TS, Garcia CB, Murta EFC. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer 2010;20(7):1154-159.
Chun S, Shin K, Kim KH, Kim HY, Eo W, Lee JY, et al. The Neutrophil-Lymphocyte Ratio Predicts Recurrence of Cervical Intraepithelial Neoplasia. J Cancer. 2017;15;8(12):2205-211.
Farzaneh F, Faghih N, Hosseini MS, Arab M, Ashrafganjoei T, et al. Evaluation of Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Cervical Intraepithelial Neoplasia Recurrence. Asian Pac J Cancer Prev. 2019;20(8):2365-372.
Lima PSV, Mantoani PTS, Murta EFC, Nomelini RS. Laboratory parameters as predictors of prognosis in uterine cervical neoplasia. Eur J Obstet Gynecol Reprod Biol. 2021;256:391-96.
Han X, Liu S, Yang G, Hosseinifard H, Imani S, Yang L, Maghsoudloo M, et al. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies. Gynecol Oncol. 2021;160(1):351-60.
Tas M, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer. J Oncol. 2019; 29;2019:2476082.
Chauhan R, Trivedi V, Rani R, Singh U, Singh K. Pre-treatment hematological parameters as a cost effective predictive marker for response to concurrent chemo radiation in locally advanced cervical cancer. Cancer Treat Res Commun. 2022; 22;31:100539.
Sharma D, Singh G. Thrombocytosis in gynecological cancers. J Cancer Res Ther. 2017; 13(2):193-97.
Wang JM, Wang Y, Huang YQ, Wang H, Zhu J, Shi JP, et al. Prognostic Values of Platelet-Associated Indicators in Resectable Cervical Cancer. Dose Response 2019;17(3):1559325819874199.
Wang H, Chen WM, Zhou YH, Shi JP, Huang YQ, Wang WJ. Combined PLT and NE to predict the prognosis of patients with locally advanced cervical cancer. Sci Rep. 2020;10(1):11210.
Cheng J, Zeng Z, Ye Q, Zhang Y, Yan R, Liang C, et al. The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(15):24327-336.
Zheng RR, Huang XX, Jin C, Zhuang XX, Ye LC, Zheng FY, et al. Preoperative platelet count improves the prognostic prediction of the FIGO staging system for operable cervical cancer patients. Clin Chim Acta. 2017;473:198-203.
